

Literatuur

1. Ehrlich P. Das Sauerstoff-Bedürfniss des Organismus. Eine Farbenanalytische Studie. Berlin: August Hirschwald; 1885.
2. Goldmann EE. Vitalfärbung am Zentralnervensystem: Beitrag zur Physio-Pathologie des Plexus chorioideus und der Hirnhäute. Berlin: Königl. Akademie der Wissenschaften, 1913.
3. Bartanusz V, Jezova D, Alajajian B, et al. The blood-spinal cord barrier: morphology and clinical implications.
4. Ganong WF. Circumventricular organs: Definition and role in the regulation of endocrine and autonomic function. *Clin Exp Pharmacol Physiol* 2000; 27(5-6): 422–27.
5. Marques F, Sousa JC, Brito MA, et al. The choroid plexus in health and in disease: dialogues into and out of the brain. *Neurobiol Dis* 2017; 107: 32-40.
6. Varatharaj A, Galea I. The blood-brain barrier in systemic inflammation. *Brain Behav Immun* [Internet] 2017; 60: 1-12. <http://dx.doi.org/10.1016/j.bbi.2016.03.010>.
7. Pardridge WM. Drug transport across the blood-brain barrier. *J Cereb Blood Flow Metab* 2012; 32(11): 1959-72.
8. Kadry H, Noorani B, Cucullo L. A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity. *Fluids Barriers CNS* [Internet] 2020; 17(1): 1-24. <https://doi.org/10.1186/s12987-020-00230-3>.
9. Keep RF, Zhou N, Xiang J, et al. Vascular disruption and blood-brain barrier dysfunction in intracerebral hemorrhage. *Fluids Barriers CNS* 2014; 11(1): 1-13.
10. Lee JM, Zhai G, Liu Q, et al. Vascular permeability precedes spontaneous intracerebral hemorrhage in stroke-prone spontaneously hypertensive rats. *Stroke* 2007; 38(12): 3289-91.
11. Najjar S, Najjar A, Chong DJ, et al. Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports. *J Neuroinflammation* 2020; 17(1): 1-14.
12. Dahm T, Rudolph H, Schwerk C, et al. Neuroinvasion and inflammation in viral central nervous system infections. *Mediators Inflamm* 2016; 2016: 8562805.
13. Cain MD, Salimi H, Diamond MS, et al. Mechanisms of pathogen invasion into the central nervous system. *Neuron* [Internet] 2019; 103(5): 771-83. <https://doi.org/10.1016/j.neuron.2019.07.015>.
14. Kim KS. Investigating bacterial penetration of the blood-brain barrier for the pathogenesis, prevention, and therapy of bacterial meningitis. *ACS Infect Dis* 2020; 6(1): 34-42.
15. Rüber T, David B, Luchters G, et al. Evidence for peri-ictal blood-brain barrier dysfunction in patients with epilepsy. *Brain* 2018; 141(10): 2952-65.
16. Marchi N, Angelov L, Masaryk T, et al. Seizure-promoting effect of blood-brain barrier disruption. *Epilepsia* 2007; 48(4): 732-42.
17. Hay JR, Johnson VE, Young AMH, et al. Blood-brain barrier disruption is an early event that may persist for many years after traumatic brain injury in humans. *J Neuropathol Exp Neurol* [Internet] 2015 [cited 2021 Nov 18]; 74(12): 1147-57. <https://pubmed-ncbi-nlm-nih-gov.ru.idm.oclc.org/26574669/>.
18. Cash A, Theus MH. Mechanisms of blood-brain barrier dysfunction in traumatic brain injury. *Int J Mol Sci* 2020; 21(9): 3344.
19. Sweeney MD, Zhao Z, Montagne A, et al. Blood-brain barrier: from physiology to disease and back. *Physiol Rev* [Internet] 2019 Jan 1 [cited 2021 Nov 18]; 99(1): 21-78. <https://pubmed-ncbi-nlm-nih-gov.ru.idm.oclc.org/30280653/>.
20. Bartels AL, Willemsen ATM, Kortekaas R, et al. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA. *J Neural Transm* 2008; 115(7): 1001-9.
21. Minagar A, Alexander JS. Blood-brain barrier disruption in multiple sclerosis. *Mult Scler* 2003; 9(6): 540-9.
22. Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. *Nat Rev Cancer* [Internet] 2020; 20(1): 26-41. <http://dx.doi.org/10.1038/s41568-019-0205-x>.
23. Banks WA. Blood-brain barrier transport of cytokines: a mechanism for neuropathology. *Curr Pharm Des* 2005; 11(8): 973-84.
24. Pardridge WM. CSF, blood-brain barrier, and brain drug delivery. *Expert Opin Drug Deliv* [Internet] 2016; 13(7): 963-75. <http://dx.doi.org/10.1517/17425247.2016.1171315>.
25. Urquhart BL, Kim RB. Blood-brain barrier transporters and response to CNS-active drugs. *Eur J Clin Pharmacol* [Internet] 2009 Nov [cited 2021 Nov 18]; 65(11): 1063-70. <https://pubmed-ncbi-nlm-nih-gov.ru.idm.oclc.org/19727692/>.
26. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics. *Clin Pharmacokinet* 2003; 42(1): 59-98.

27. Tolle-Sander S, Rautio J, Wring S, et al. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. *Pharm Res* [Internet] 2003 [cited 2021 Nov 18]; 20(5): 757-64. <https://pubmed.ncbi.nlm.nih.gov/12751631/>.
28. Chaves C, Remiao F, Cisternino S, et al. Opioids and the blood-brain barrier: a dynamic interaction with consequences on drug disposition in brain. *Curr Neuropharmacol* 2017; 15(8): 1156-73.
29. Fuchs-Buder T, Strowitzki M, Rentsch K, et al. Concentration of rocuronium in cerebrospinal fluid of patients undergoing cerebral aneurysm clipping. *Br J Anaesth* 2004; 92(3): 419-21.
30. Löscher W, Friedman A. Structural, molecular, and functional alterations of the blood-brain barrier during epileptogenesis and epilepsy: a cause, consequence, or both? *Int J Mol Sci* 2020; 21(2): 1-19.
31. Rempe RG, Hartz AMS, Bauer B. Matrix metalloproteinases in the brain and blood-brain barrier: versatile breakers and makers. *J Cereb Blood Flow Metab* 2016; 36(9): 1481-507.
32. Lampl Y, Boaz M, Gilad R, et al. Minocycline treatment in acute stroke. *Curr Atheroscler Rep* 2008; 10(4): 286-87.
33. Michinaga S, Koyama Y. Pathogenesis of brain edema and investigation into anti-edema drugs. *Int J Mol Sci* 2015; 16(5): 9949-75.
34. Ollidashi F, Muzha I, Filipi N, et al. Effect of intravenous corticosteroids on death within 14 days in 10,008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial. *Lancet* 2004; 364(9442): 1321-28.

De auteurs hebben geen financiële banden met de farmaceutische industrie, ontvangen geen onderzoeksgeld van commerciële partijen en hebben geen bedrijfsbelangen of andersoortige financiële relaties met betrekking tot dit onderwerp.